ÐÇ¿ÕÓéÀÖ¹ÙÍø

Published in Morbidity and Mortality Weekly Report (MMWR)

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the ÐÇ¿ÕÓéÀÖ¹ÙÍø regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Director and, if adopted, are published as official ÐÇ¿ÕÓéÀÖ¹ÙÍø/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).

CURRENT RSV vaccine immunizations

MMWR; August 15, 2024 / 73(32);696-702
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
See also:
Respiratory Syncytial Virus (RSV) Vaccine Safety
FDA self-controlled case series GBS update

MMWR; October 13, 2023 / 72(41);1115–1122
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version

MMWR; August 25, 2023 / 72(34);920–925
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version

ARCHIVED RSV immunization publications

For your convenience, these archived publications can be used for historical and research purposes.

MMWR; July 21, 2023;72(29);793–801
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version